HomeCompareLCI vs EQR

LCI vs EQR: Dividend Comparison 2026

LCI yields 291.76% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LCI wins by $1256.27M in total portfolio value
10 years
LCI
LCI
● Live price
291.76%
Share price
$0.69
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1256.32M
Annual income
$750,381,665.69
Full LCI calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — LCI vs EQR

📍 LCI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLCIEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LCI + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LCI pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LCI
Annual income on $10K today (after 15% tax)
$24,799.42/yr
After 10yr DRIP, annual income (after tax)
$637,824,415.84/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, LCI beats the other by $637,819,761.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LCI + EQR for your $10,000?

LCI: 50%EQR: 50%
100% EQR50/50100% LCI
Portfolio after 10yr
$628.18M
Annual income
$375,193,570.65/yr
Blended yield
59.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

LCI
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-5.3
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LCI buys
0
EQR buys
0
No recent congressional trades found for LCI or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLCIEQR
Forward yield291.76%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$1256.32M$47.8K
Annual income after 10y$750,381,665.69$5,475.61
Total dividends collected$1205.12M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: LCI vs EQR ($10,000, DRIP)

YearLCI PortfolioLCI Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$39,876$29,175.78$11,380$679.82+$28.5KLCI
2$151,397$108,729.65$13,014$837.25+$138.4KLCI
3$547,803$385,808.25$14,961$1,036.20+$532.8KLCI
4$1,890,803$1,304,654.20$17,297$1,289.22+$1.87MLCI
5$6,231,722$4,208,562.14$20,121$1,613.15+$6.21MLCI
6$19,631,126$12,963,183.99$23,561$2,030.84+$19.61MLCI
7$59,170,289$38,164,983.69$27,783$2,573.54+$59.14MLCI
8$170,819,960$107,507,751.72$33,013$3,284.39+$170.79MLCI
9$472,839,421$290,062,063.35$39,547$4,223.51+$472.80MLCI
10$1,256,319,846$750,381,665.69$47,791$5,475.61+$1256.27MLCI

LCI vs EQR: Complete Analysis 2026

LCIStock

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.

Full LCI Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this LCI vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LCI vs SCHDLCI vs JEPILCI vs OLCI vs KOLCI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.